Section Arrow
CARM.NASDAQ
- Carisma Therapeutics
Quotes are at least 15-min delayed:2024/05/16 19:03 EDT
Last
 1.37
-0.03 (-2.14%)
Day High 
1.43 
Prev. Close
1.4 
1-M High
1.91 
Volume 
185.49K 
Bid
1.36
Ask
1.4
Day Low
1.35 
Open
1.43 
1-M Low
1.345 
Market Cap 
58.16M 
Currency USD 
P/E -- 
%Yield 57.25 
10-SMA 1.52 
20-SMA 1.6 
50-SMA 1.96 
52-W High 9.7662 
52-W Low 1.345 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.12/-0.99
Enterprise Value
59.35M
Balance Sheet
Book Value Per Share
0.26
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.92M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1001+0.0224+28.83%-- 
DNAGinkgo Bioworks Holdings0.839-0.0001-0.01%-- 
NBYNovaBay Pharmaceuticals0.12+0.0155+14.83%-- 
JAGXJaguar Health0.2867+0.0316+12.39%-- 
NVAXNovavax14.4+1.5+11.63%-- 
Quotes are at least 15-min delayed:2024/05/16 19:03 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.